Item 8.01 Other Events
On November 3, 2006, NovaDel Pharma Inc. (“NovaDel”), a Delaware corporation, issued a press release announcing that NitroMist™ (Nitroglycerin Lingual Aerosol) has been approved by the U.S. Food and Drug Administration for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. NitroMist™ is NovaDel’s first approval and utilizes its proprietary oral spray technology. The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release of NovaDel Pharma Inc. dated November 3, 2006, titled “NovaDel Pharma Receives FDA Approval of NitroMist™.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovaDel Pharma Inc.
|
By |
/s/ Michael E Spicer |
|
Name |
Michael E Spicer |
|
Title |
Chief Financial Officer |
Date: November 6, 2006
F 888.329.6696